ANCA-ASSOCIATED VASCULITIS (AAV)
Clinical trials for ANCA-ASSOCIATED VASCULITIS (AAV) explained in plain language.
Never miss a new study
Get alerted when new ANCA-ASSOCIATED VASCULITIS (AAV) trials appear
Sign up with your email to follow new studies for ANCA-ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take aim at lupus and MS
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune responses in autoimmune diseases like lupus, scleroderma, and multiple sclerosis. The main goal is to check safety and how the body h…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
Could CAR-T therapy tame severe vasculitis? new trial launches
Disease control Recruiting nowThis study tests a new treatment called rapcabtagene autoleucel (a CAR-T cell therapy) against standard care for people with severe active vasculitis (GPA or MPA). About 126 adults aged 18–75 with confirmed ANCA antibodies and active disease will be enrolled. The goal is to see i…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:59 UTC
-
Immune cell therapy shows promise for tough autoimmune conditions
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't improved with standard treatments. The goal is to see if a single infusion can safely …
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment is given as a one-time infusion and aims…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
First human trial of mRNA injection for lupus and other autoimmune conditions begins
Disease control Recruiting nowThis early-phase study tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and side effects, not to cure the disease. Participants receive the drug by IV and are monitored closel…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New hope for rare blood vessel disease: experimental drug aims to calm immune attack
Disease control Recruiting nowThis study tests whether adding BDB-001 to standard treatments (cyclophosphamide/azathioprine or rituximab) helps more people with ANCA vasculitis reach remission. About 300 adults with active GPA or MPA will receive either BDB-001 or a placebo. The goal is to reduce disease acti…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a universal CAR T-cell therapy designed to target and destroy certain immune cells (those with CD19 or BCMA markers) that drive autoimmune diseases. It enrolls 12 adults with severe conditions like lupus, scleroderma, or vasculitis that have not respo…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New cell therapy trial offers hope for young people with rare autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called Descartes-08 in 50 children, adolescents, and young adults with four autoimmune diseases: lupus, vasculitis, myasthenia gravis, and dermatomyositis. The goal is to see if it is safe and can control moderate disease symptoms. Participants re…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Blood test could end guesswork in treating arthritis and autoimmune diseases
Diagnosis Recruiting nowThis study is testing a new blood test that may help doctors choose the most effective medicine for people with rheumatic diseases like rheumatoid arthritis, lupus, and vasculitis. Researchers will take a blood sample and use it to see how a person's immune cells react to differe…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated May 20, 2026 11:54 UTC
-
Full-Body scanner could spot hidden inflammation and heart danger
Knowledge-focused Recruiting nowThis study is testing whether a special full-body PET scan can more accurately detect active disease and long-term heart risk in people with ANCA vasculitis, a rare autoimmune condition that inflames blood vessels. Researchers will scan up to 90 patients with active disease and 3…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC